A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
نویسندگان
چکیده
منابع مشابه
A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
BACKGROUND In Japan, selegiline has been approved for combination therapy with levodopa for Parkinson disease (PD). We conducted a trial of selegiline monotherapy for early PD. METHODS In this 12-week controlled phase III trial, a total of 292 subjects were randomized to receive placebo (n = 146) (full analysis set 140) or selegiline (n = 146) (full analysis set 139). The primary outcome meas...
متن کاملTransdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
OBJECTIVE To assess the response to the rotigotine transdermal system (Neupro; Schwarz Pharma Ltd, Monheim, Germany), a nonergolinic dopamine agonist, in patients with early Parkinson disease. DESIGN Randomized, double-blind, multicenter, placebo-controlled study. SETTING Fifty sites in the United States and Canada. PATIENTS Two hundred seventy-seven patients with early Parkinson disease....
متن کاملA Randomized, Double-Blind, Placebo-Controlled Trial
Results: The cumulative number of gadoliniumenhancing MRI lesions during the first 6 months were similar in the -3 fatty acids and placebo groups (median difference, 1; 95% CI, 0 to 3; P=.09). No difference in relapse rate was detected after 6 (median difference, 0; 95% CI, 0 to 0; P=.54) or 24 (median difference, 0; 95% CI, 0 to 0; P=.72) months. The proportion of patients without disability p...
متن کاملA Randomized, Placebo-Controlled Double-Blind Trial
The efficacy and safety of pentoxifylline were assessed in 297 adult patients with ischemic stroke in a molticenter, doable-blind, randomized and placebo-controlled trial. Treatment was started within 12 hoars after the stroke onset Study medication was administered intravenously continuously (16 mg/kg/day, maximum 1,200 mg/day) for 3 days and per os (400 mg ti.d.) for the remainder of 28 days....
متن کاملA Randomized, Double-Blind, placebo-Controlled Trial
Method: Five hundred forty-two outpatients with bipolar I (N=360) or 11 (N=182) disorder experiencing a major depressive episode (DSM-IV) were randomly assigned to 8 weeks of quetiapine (600 or 300 mgl day) or placebo. The prima ry efficacy measure was mean change from base))ne to week 8 in the Montgomery-Asberg Depression Rating Scale total score. Additional efficacy assessments included the H...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Neuropharmacology
سال: 2017
ISSN: 1537-162X,0362-5664
DOI: 10.1097/wnf.0000000000000239